Compare Sanofi SA (SNY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs United States Oil ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while United States Oil ETF trades at $151.14. The key difference: Sanofi SA pays a 5.61% dividend while United States Oil ETF pays none, and United States Oil ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | USO | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | — |
52-Week High | $52.34 | $152.96 |
52-Week Low | $41.33 | $66.17 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
USO is trading at $146.03, up 2.87% amid strong bullish momentum driven by escalating Middle East tensions pushing oil prices higher. The technical picture shows overwhelming bullish signals with moving averages strongly supporting upward momentum, though oscillators indicate potential overbought conditions. Recent news highlights supply disruptions in the Strait of Hormuz driving Brent crude above $100 per barrel, creating favorable conditions for energy sector performance.
The outlook remains positive as geopolitical tensions continue to support oil prices, though elevated RSI levels suggest near-term consolidation risk. Key resistance at $147-$150 presents the next challenge, while support at $144-$142 provides downside protection. Energy sector strength appears sustainable given ongoing supply constraints and OPEC+ production discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
